Latus Bio Secures $42 Million for Huntington's Disease Gene Therapy Trial
Latus Bio has successfully raised $42 million to advance its gene therapy aimed at treating Huntington's disease, with plans to seek FDA approval for a clinical trial.
Editorial Staff
1 min read
Updated 5 days ago
Latus Bio has announced the completion of a $42 million funding round, which will support its efforts to develop a gene therapy for Huntington's disease.
The company is preparing to submit an application to the FDA for approval to initiate a clinical trial focused on this promising treatment.
Huntington's disease, a progressive neurodegenerative disorder, currently has limited treatment options, making advancements in this area particularly significant.